After a slew of M&A deals throughout the first month of 2018, including Celgene’s buyout of Juno Therapeutics for $9 billion and Sanofi’s spending spree to acquire Bioverativ for $11.6 billion and Ablynx for $4.8 billion, many in the industry are asking who will be the next to make a deal.
Ook interessant voor je
Reageer